8,800 results match your criteria Breast cancer research and treatment[Journal]


Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.

Breast Cancer Res Treat 2019 Feb 15. Epub 2019 Feb 15.

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Purpose: The metabolic etiology of breast cancer has been explored in the past several years using metabolomics. However, most of these studies only included non-Hispanic White individuals.

Methods: To fill this gap, we performed a two-step (discovery and validation) metabolomics profiling in plasma samples from 358 breast cancer patients and 138 healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05165-4DOI Listing
February 2019

Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit.

Breast Cancer Res Treat 2019 Feb 13. Epub 2019 Feb 13.

Department of Surgical Oncology, Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.

Background: Invasive lobular carcinomas (ILCs) represent approximately 10% of all breast cancers. Despite this high frequency, benefit of adjuvant chemotherapy (CT) is still unclear.

Methods: Our objective was to investigate the impact of CT on survival in ILC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05160-9DOI Listing
February 2019

Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.

Breast Cancer Res Treat 2019 Feb 13. Epub 2019 Feb 13.

Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands.

Purpose: The estrogen (ER), progesterone (PR), and HER2 status are essential in guiding treatment decisions in breast cancer patients. In daily life, the ER/PR/HER2 status is expected to be commonly tested twice, i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05141-yDOI Listing
February 2019

Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.

Breast Cancer Res Treat 2019 Feb 12. Epub 2019 Feb 12.

Women's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada.

Purpose: Following a diagnosis of breast cancer, BRCA mutation carriers face an increased risk of developing a second (contralateral) cancer in the unaffected breast. It is important to identify predictors of contralateral cancer in order to make informed decisions about bilateral mastectomy. The impact of bilateral salpingo-oophorectomy (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05162-7DOI Listing
February 2019

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.

Breast Cancer Res Treat 2019 Feb 12. Epub 2019 Feb 12.

Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.

Purpose: UGT2B17 gene deletion (UGT2B17*2) has been reported to affect bone health as well as the pharmacokinetics of aromatase inhibitor (AI) drugs such as exemestane. The goal of this study was to assess associations between UGT2B17 gene deletion and bone health prior to and after 24 months of AI treatment in postmenopausal women with hormone receptor positive (HR+) breast cancer.

Methods: Bone health in women with HR+ breast cancer enrolled on the prospective randomized Exemestane and Letrozole Pharmacogenetics (ELPh) trial was determined by measuring bone turnover markers (BTM) and bone mineral density (BMD) pre-treatment and after 3 BTM and 24 BMD months of treatment with either the steroidal AI exemestane or the nonsteroidal AI letrozole. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05158-3DOI Listing
February 2019
1 Read

Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.

Breast Cancer Res Treat 2019 Feb 12. Epub 2019 Feb 12.

Breast Unit, Guy's and St Thomas' NHS Foundation Trust and King's Biomedical Centre, 4th Floor, Bermondsey Wing, Great Maze Pond, London, SE1 9RT, UK.

Purpose: Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities. However, prospective DPYD genotyping has not yet been implemented in routine clinical practice. Following a previous internal review in which two patients underwent lengthy hospitalisations whilst receiving capecitabine, and were subsequently found to be DPD deficient, we initiated routine DPYD genotyping prior to starting capecitabine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05144-9DOI Listing
February 2019
2 Reads

The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients.

Breast Cancer Res Treat 2019 Feb 12. Epub 2019 Feb 12.

University of Utrecht, Utrecht, The Netherlands.

Purpose: To evaluate the impact of chemotherapy on subjective cognitive functioning according to age in a large cohort of breast cancer patients.

Methods: Within the UMBRELLA cohort, 715 patients with early-stage primary invasive breast cancer (T1-3N0-1M0) were selected. Subjective cognitive function was assessed by means of the EORTC QLQ-C30 up to 24 months and compared between patients treated with and without chemotherapy, for three different age strata (355 patients < 55 years, 240 patients aged 55-65 years, and 120 patients > 65 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05149-4DOI Listing
February 2019

Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up.

Breast Cancer Res Treat 2019 Feb 12. Epub 2019 Feb 12.

Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Background: It remains unclear whether breast cancer subtypes are associated with clinical outcome in patients without any treatment including systemic and radiation therapy as an independent entity. Understanding the survival profiles among subtypes by treatment status could impact optimal selection of treatments.

Methods: Patients were diagnosed with invasive breast cancer from the community hospitals across four geographical regions of the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05142-xDOI Listing
February 2019
1 Read

Breast sensibility after mastectomy and implant-based breast reconstruction.

Breast Cancer Res Treat 2019 Feb 12. Epub 2019 Feb 12.

Department of Plastic and Reconstructive Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.

Purpose: The aim of the study is to evaluate the level of sensible impairment after mastectomy or implant-based breast reconstruction (IBBR). In addition, factors influencing breast sensibility were evaluated.

Methods: A cross-sectional study was performed in Maastricht University Medical Center between July 2016 and August 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05137-8DOI Listing
February 2019

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.

Breast Cancer Res Treat 2019 Feb 12. Epub 2019 Feb 12.

Department of Oncology, Nottingham University Hospitals, Nottingham, NG5 1PB, UK.

Purpose: MYC transcription factor has critical roles in cell growth, proliferation, metabolism, differentiation, transformation and angiogenesis. MYC overexpression is seen in about 15% of breast cancers and linked to aggressive phenotypes. MYC overexpression also induces oxidative stress and replication stress in cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05113-8DOI Listing
February 2019

Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer.

Breast Cancer Res Treat 2019 Feb 9. Epub 2019 Feb 9.

College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150086, Heilongjiang, China.

Purpose: Genomic studies have revealed that genomic aberrations play important roles in the progression of this disease. The aim of this study was to evaluate the associations between clinical survival outcomes of the clonality and subclonality status of driver genes in breast cancer.

Methods: We performed an integrated analysis to infer the clonal status of 55 driver genes in breast cancer data from TCGA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05153-8DOI Listing
February 2019

Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.

Breast Cancer Res Treat 2019 Feb 6. Epub 2019 Feb 6.

Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, 300 George St, Suite 120, Rm 133, New Haven, CT, 06520, USA.

Purpose: African-American (AA) patients with triple-negative breast cancer (TNBC) are less likely to achieve pathologic complete response from neoadjuvant chemotherapy and have poorer prognosis than Caucasian patients with TNBC, suggesting potential biological differences by race. Immune infiltration is the most consistent predictive marker for chemotherapy response and improved prognosis in TNBC. In this study, we test the hypothesis that the immune microenvironment differs between AA and Caucasian patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05156-5DOI Listing
February 2019
2 Reads
3.940 Impact Factor

High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.

Breast Cancer Res Treat 2019 Feb 6. Epub 2019 Feb 6.

Center of Familial Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany.

Purpose: To report on 10 years of high-risk service screening with annual MRI in the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).

Methods: A cohort of 4,573 high-risk, previously unaffected women (954 BRCA1 carriers, 598 BRCA2 carriers, 3021 BRCA1/2 non-carriers) participating in the GC-HBOC surveillance program was prospectively followed. Screening outcomes for 14,142 screening rounds with MRI between 2006 and 2015 were analyzed and stratified by risk group, type of screening round, and age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05152-9DOI Listing
February 2019
2 Reads

ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness.

Breast Cancer Res Treat 2019 Feb 6. Epub 2019 Feb 6.

Department of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC, 27151, USA.

Purpose: Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer which could progress to or recur as invasive breast cancer. The underlying molecular mechanism of DCIS progression is yet poorly understood, and appropriate biomarkers to distinguish benign form of DCIS from potentially invasive tumor are urgently needed.

Methods: To identify the key regulators of DCIS progression, we performed gene-expression analysis of syngeneic breast cancer cell lines MCF10A, DCIS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05126-3DOI Listing
February 2019

Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.

Breast Cancer Res Treat 2019 Feb 5. Epub 2019 Feb 5.

Department of Medicine, Weill Cornell Medical College, New York, NY, USA.

Purpose: Asymptomatic decline in left ventricular ejection fraction (LVEF) or heart failure (HF) occurs in up to 25% of patients treated with trastuzumab and can result in incomplete breast cancer therapy. The cardiac safety of continuing trastuzumab in patients with asymptomatic LVEF decline is unknown. We report the cardiac outcomes of patients treated with trastuzumab after a significant asymptomatic LVEF decline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05139-6DOI Listing
February 2019
3 Reads

Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.

Breast Cancer Res Treat 2019 Feb 4. Epub 2019 Feb 4.

Department of Surgery, Severance Hospital, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Republic of Korea.

Purpose: The Z0011 trial demonstrated that axillary dissection (ALND) could be omitted during breast-conserving therapy for cT1-2N0 breast cancers with 1-2 metastatic SLNs. However, that result has not been validated in a larger cohort and the significance of the small number of SLNs remains unclear. This study aimed to validate the Z0011 results within an Asian Z0011-eligible cohort and determine whether the number of sentinel lymph nodes (SLNs) influenced the Z0011-based outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05157-4DOI Listing
February 2019

An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.

Breast Cancer Res Treat 2019 Feb 4. Epub 2019 Feb 4.

Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China.

Purpose: To identify a lncRNA signature to predict survival of breast cancer (BRCA) patients.

Methods: A total of 1222 BRCA case and control datasets were downloaded from the TCGA database. The weighted gene co-expression network analysis of differentially expressed mRNAs was performed to generate the modules associated with BRCA overall survival status and further construct a hub on competing endogenous RNA (ceRNA) network. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05147-6DOI Listing
February 2019
3.940 Impact Factor

Efficacy of self-administered complex decongestive therapy on breast cancer-related lymphedema: a single-blind randomized controlled trial.

Breast Cancer Res Treat 2019 Feb 2. Epub 2019 Feb 2.

LAM-Motion Analysis Laboratory, San Sebastiano Hospital, Correggio, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Purpose: After surgery, breast cancer-related lymphedema (BCRL) is a frequent chronic condition. The complex decongestive therapy (CDT) delivered by physiotherapists at hospitals is the state-of-the-art treatment choice. As lymphedema requires continuous management, we designed a 1-month-long course to train women to professionally carry out a self-administered CDT (saCDT) and tested its efficacy while keeping the benefits of CDT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05136-9DOI Listing
February 2019
1 Read

Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.

Breast Cancer Res Treat 2019 Feb 2. Epub 2019 Feb 2.

Department of Pathology and Laboratory Medicine, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Lu, Guangzhou, 510080, People's Republic of China.

Objectives: Human epidermal growth factor receptor 2 (HER2, ERBB2) is a valuable prognostic and predictive biomarker in breast cancer. Accurate assessment of HER2 status is essential in selecting the patients with invasive breast cancer who will likely response to HER2-targeted therapies. Some major modifications in the diagnostic recommendation for fluorescence in situ hybridization (FISH) have been made in the updated 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologist (CAP) guideline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05148-5DOI Listing
February 2019
2 Reads
3.940 Impact Factor

S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells.

Breast Cancer Res Treat 2019 Feb 2. Epub 2019 Feb 2.

Department of Medicine, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Purpose: Many transformed cells and embryonic stem cells are dependent on the biosynthesis of the universal methyl-donor S-adenosylmethionine (SAM) from methionine by the enzyme MAT2A to maintain their epigenome. We hypothesized that cancer stem cells (CSCs) rely on SAM biosynthesis and that the combination of methionine depletion and MAT2A inhibition would eradicate CSCs.

Methods: Human triple (ER/PR/HER2)-negative breast carcinoma (TNBC) cell lines were cultured as CSC-enriched mammospheres in control or methionine-free media. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05146-7DOI Listing
February 2019
2 Reads

Tamoxifen and pregnancy: an absolute contraindication?

Breast Cancer Res Treat 2019 Feb 1. Epub 2019 Feb 1.

Department of Gynecologic Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

Purpose: Breast cancer is the most common malignancy among young women of reproductive age. Adjuvant treatment with tamoxifen reduces the risk of recurrence in hormone-sensitive breast cancer. However, the use of tamoxifen is considered contraindicated during pregnancy, because of a limited number of case reports demonstrating potential adverse effects on the fetus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05154-7DOI Listing
February 2019

HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment.

Authors:
Kadri Altundag

Breast Cancer Res Treat 2019 Feb 1. Epub 2019 Feb 1.

MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800, Ankara, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05151-wDOI Listing
February 2019
1 Read

Factors influencing the use of extended adjuvant endocrine therapy.

Breast Cancer Res Treat 2019 Jan 31. Epub 2019 Jan 31.

Division of Oncology, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr., #5513, Salt Lake City, UT, 84112, USA.

Purpose: Extending adjuvant endocrine therapy (ET) beyond 5 years has been shown to improve outcomes in breast cancer; however, limited data are available about if and why women pursue extended ET. The primary objective was to estimate the proportion of women who were willing to receive extended ET if recommended by their physician and secondarily, to determine what factors were associated with this decision.

Methods: This descriptive cross-sectional study surveyed 131 women with AJCC 7th Edition stages I-III breast cancer who had been taking adjuvant ET for 3-5 years. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05145-8
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05145-8DOI Listing
January 2019
3 Reads

The effects of psychosexual counseling on sexual quality of life and function in Iranian breast cancer survivors: a randomized controlled trial.

Breast Cancer Res Treat 2019 Jan 30. Epub 2019 Jan 30.

Center for Health Related Social and Behavioral Sciences Research Shahroud, University of Medical Sciences, Shahroud, Iran.

Background: Considering different dimensions of life, special sex life for survivors of breast cancer (BC) is important because their life expectancy has increased.

Objective: We designed this study to improve the sexual function, satisfaction and quality of sexual life.

Methods: In a randomized controlled clinical trial study, from a total 286 breast cancer survivors (BCS), 118 women enrolled to the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05140-zDOI Listing
January 2019

Microchipping the breast: an effective new technology for localizing non-palpable breast lesions for surgery.

Breast Cancer Res Treat 2019 Jan 28. Epub 2019 Jan 28.

Department of Radiologic Sciences, University of California Los Angeles, 1260 15th Street, Santa Monica, CA, 90404, USA.

Purpose: Use of a wire to localize a non-palpable breast lesion for surgery is standard but archaic. We sought to evaluate a new radiofrequency localization system (RFLS) as an effective, non-radioactive alternative to the wire.

Methods: Patients who required surgical excision of a non-palpable breast lesion were consented for the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05143-wDOI Listing
January 2019
1 Read

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.

Breast Cancer Res Treat 2019 Jan 24. Epub 2019 Jan 24.

Department of Cancer and Surgery, Faculty of Medicine, Imperial College London, Du Cane Road, London, W12 0NN, UK.

Purpose: The prognostic and predictive values of the MAPK/AKT/ERα phosphorylation axis (pT202/T204MAPK, pT308AKT, pS473AKT, pS118ERα and pS167ERα) in primary tumours were assessed to determine whether these markers can differentiate between patient responses for switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane and continued tamoxifen monotherapy in the Intergroup Exemestane Study (IES).

Methods: Of the 4724 patients in IES, 1506 were managed in a subset of centres (N = 89) participating in PathIES. These centres recruited 1282 (85%, 1282/1506) women into PathIES of whom 1036 had phospho-marker data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05110-xDOI Listing
January 2019

Differences between screen-detected and interval breast cancers among BRCA mutation carriers.

Breast Cancer Res Treat 2019 Jan 23. Epub 2019 Jan 23.

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: BRCA mutation carriers have an elevated lifetime breast cancer risk and remain at risk for interval cancer development. We sought to compare BRCA mutation carriers with screen-detected versus interval breast cancers.

Methods: Women with a known BRCA mutation prior to a breast cancer diagnosis were identified. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-018-05123-6
Publisher Site
http://dx.doi.org/10.1007/s10549-018-05123-6DOI Listing
January 2019
3 Reads

Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.

Breast Cancer Res Treat 2019 Jan 23. Epub 2019 Jan 23.

Huntsman Cancer Institute, University of Utah, Salt Lake City, USA.

Background: We recently showed PAM50 gene expression data can be represented by five quantitative, orthogonal, multi-gene breast tumor traits. These novel tumor 'dimensions' were superior to categorical intrinsic subtypes for clustering in high-risk breast cancer pedigrees, indicating potential to represent underlying genetic susceptibilities and biological pathways. Here we explore the prognostic and predictive utility of these dimensions in a sub-study of GEICAM/9906, a Phase III randomized prospective clinical trial of paclitaxel in breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05097-5DOI Listing
January 2019

Prognostic effects of abnormal DNA damage response protein expression in breast cancer.

Breast Cancer Res Treat 2019 Jan 22. Epub 2019 Jan 22.

Translational Medicine, Seoul National University College of Medicine, Seoul, Korea.

Purpose: We aimed to explore the expression of DNA damage response machinery proteins and their integrated prognostic value in different subgroups of breast cancer.

Methods: Expression of NBS1, BRCA1, BRCA2, ATM, and p53 was determined by immunohistochemistry in 419 surgically resected breast tumors.

Results: Loss of NBS1, BRCA1, ATM, and abnormal p53 expression was significantly associated with lower disease-free survival rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05128-9DOI Listing
January 2019

The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.

Breast Cancer Res Treat 2019 Jan 22. Epub 2019 Jan 22.

Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, Nottingham City Hospital, University of Nottingham, Hucknall Road, Nottingham, NG5 1PB, UK.

Purpose: Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity, and patient outcome. Glutamine availability for growth and progression of BC is important in several BC subtypes. This study aimed to evaluate the biological and prognostic role of the combined expression of key glutamine transporters, SLC1A5, SLC7A5, and SLC3A2 in BC with emphasis on the intrinsic molecular subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05111-wDOI Listing
January 2019

The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea.

Breast Cancer Res Treat 2019 Jan 22. Epub 2019 Jan 22.

City of Hope Medical Group, Inc, 1500 E Duarte Rd, Duarte, CA, 91010, USA.

Purpose: Diarrhea is recognized as a common adverse event associated with tyrosine kinase inhibitors (TKIs), with those targeting the ErbB family of receptors being associated with the highest rate of diarrhea.

Methods: This paper reviews data on the incidence, timing, and duration of diarrhea associated with US Food and Drug Administration-approved ErbB family-targeted TKIs from the published literature, and sets forth recommendations for management.

Results: In the absence of anti-diarrheal prophylaxis the incidence of any-grade diarrhea varies and typically occurs early during the course of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05102-xDOI Listing
January 2019
2 Reads

Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk.

Breast Cancer Res Treat 2019 Jan 21. Epub 2019 Jan 21.

Comprehensive Breast Health Center, Brigham and Women's Hospital, Boston, MA, USA.

Purpose: Existing high-risk clinic models focus on patients with known risk factors, potentially missing many high-risk patients. Here we describe our experience implementing universal risk assessment in an ambulatory breast center.

Methods: Since May 2017, all breast center patients completed a customized intake survey addressing known breast cancer risk factors and lifestyle choices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05116-5DOI Listing
January 2019

Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?

Breast Cancer Res Treat 2019 Jan 21. Epub 2019 Jan 21.

Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA.

Purpose: Atypical ductal hyperplasia (ADH) significantly increases the risk of breast cancer in women. However, little is known about the implications of ADH in men.

Methods: Review of 932 males with breast pathology was performed to identify cases of ADH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05117-4DOI Listing
January 2019
1 Read

Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.

Breast Cancer Res Treat 2019 Jan 18. Epub 2019 Jan 18.

Department of Oncology and Pathology, CCK, Karolinska Institutet, 17176, Stockholm, Sweden.

Purpose: The accuracy of predictive and prognostic biomarker assessment in breast cancer is paramount since these guide therapy decisions. The aim was to investigate the concordance of biomarkers and immunohistochemical (IHC)-based surrogate tumor subtypes between core needle biopsies (CNB) and consecutive paired breast cancer surgical resections.

Methods: This retrospective study comprised two cohorts of patients with primary breast cancer diagnosed between 2016 and 2017: one treated with primary surgery (n = 526) and one with neoadjuvant chemotherapy (NAC) (n = 216). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-018-05119-2
Publisher Site
http://dx.doi.org/10.1007/s10549-018-05119-2DOI Listing
January 2019
9 Reads

Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.

Breast Cancer Res Treat 2019 Jan 18. Epub 2019 Jan 18.

Medical Oncology Unit, ASST Bergamo Ovest, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy.

Background: Several trials have demonstrated the benefit of anti-CDK4/6 inhibitors plus endocrine therapy in estrogen receptor-positive (ER+) advanced breast cancer (BC), in first or subsequent lines of therapy. However, due to the lack of direct/indirect comparisons, there are no data demonstrating the superiority of one drug over the other. We compared the effectiveness of palbociclib, ribociclib, and abemaciclib in advanced ER + BC via an indirect adjusted analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05133-yDOI Listing
January 2019
2 Reads

Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.

Breast Cancer Res Treat 2019 Jan 18. Epub 2019 Jan 18.

Department of Research & Evaluation, Kaiser Permanente Southern California, 100 South Los Robles, 2nd Floor, Pasadena, CA, 91101, USA.

Purpose: Venous thromboembolism (VTE) is the second most common cause of death in hospitalized patients with cancer, and cancer treatments may exacerbate VTE risk. Patients with hormone-receptor-positive breast cancer usually receive adjuvant endocrine therapy for 5 years or longer. The aim of this study is to examine VTE risk following long-term use of aromatase inhibitor (AI) compared with tamoxifen use among breast cancer survivors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05086-8DOI Listing
January 2019
6 Reads

Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.

Breast Cancer Res Treat 2019 Jan 17. Epub 2019 Jan 17.

Department of Medicine, Breast Unit, The Royal Marsden NHS Foundation Trust, 203 Fulham Rd, Chelsea, London, SW3 6JJ, UK.

Purpose: Palbociclib is approved in 1st line for hormone receptor (HR)-positive HER2-negative advanced breast cancer (ABC). A Compassionate Access Programme previously allowed patients to receive it in 4th line. However, Palbociclib has not been specifically tested in this population. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05134-x
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05134-xDOI Listing
January 2019
7 Reads
3.940 Impact Factor

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.

Breast Cancer Res Treat 2019 Jan 11. Epub 2019 Jan 11.

Department of Oncology, Hôpitaux Universitaires de Genève, 4 Rue Gabrielle Perret-Gentil, 1205, Geneva, Switzerland.

Purpose: BRCA1 and BRCA2 proteins are central to DNA repair process through homologous recombination. We hypothesize that BRCA1/BRCA2 mutation carriers may exhibit increased hematological toxicity when receiving genotoxic chemotherapy.

Methods: We included women with primary breast cancers screened for BRCA1/BRCA2 germline mutations and treated with (neo)adjuvant chemotherapy in Geneva (Swiss cohort). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05127-2DOI Listing
January 2019
2 Reads

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.

Breast Cancer Res Treat 2019 Jan 10. Epub 2019 Jan 10.

Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.

Purpose: In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-018-05125-4
Publisher Site
http://dx.doi.org/10.1007/s10549-018-05125-4DOI Listing
January 2019
15 Reads

Health-related quality of life of breast cancer patients in the Eastern Mediterranean region: a systematic review and meta-analysis.

Breast Cancer Res Treat 2019 Jan 10. Epub 2019 Jan 10.

Nursing Care Research Center and School of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran.

Purpose: Breast cancer is the most common type of cancer in women around the world, and this applies to the Middle East as well. The goal of all medical care and treatment is to improve the quality of life (QoL) of patients. Accordingly, the present study aimed at evaluating the QoL of patients with breast cancer in the Middle East region. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05131-0
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05131-0DOI Listing
January 2019
5 Reads
3.940 Impact Factor

Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis.

Breast Cancer Res Treat 2019 Jan 10. Epub 2019 Jan 10.

Department of Zoology, Faculty of Science, Cairo University, 12613, Giza, Egypt.

Purpose: Plasmacytoid dendritic cells (PDCs) infiltration into breast cancer tissues is associated with poor prognosis. Also, CXCR4 shows compelling evidences to be exploited by cancer cells to migrate to distant sites. The present study investigated lymph node metastasis in the light of PDCs infiltration and the potential cross talk with CXCR4/SDF-1 chemokine axis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05129-8DOI Listing
January 2019
1 Read

Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Breast Cancer Res Treat 2019 Jan 10. Epub 2019 Jan 10.

West German Study Group, Ludwig-Weber-Str. 15, 41061, Moenchengladbach, Germany.

The article Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, written by Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Wolfram Malter, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer, Andrea Stefek, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, Cornelia Liedtke, Calvin Chao, Steven Shak, Rachel Wuerstlein, Hans H. Kreipe, Nadia Harbeck, was originally published electronically on the publisher's internet portal (currently SpringerLink) on June 29, 2017 without open access. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05105-8DOI Listing
January 2019
3 Reads

PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review.

Breast Cancer Res Treat 2019 Jan 10. Epub 2019 Jan 10.

Dept. of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej, 2730, Herlev, Denmark.

Purpose: To systematically review the literature on the expression of PD-L1 in primary BC, variation of expression between subtypes and effect on overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS). Additionally, for studies in the neoadjuvant setting, we have reviewed the ability of PD-L1 to predict pathological complete response (pCR).

Methods: Articles included in this review were retrieved by searching PubMed (1966-2018) and EMBASE (1980-2018). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05130-1
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05130-1DOI Listing
January 2019
7 Reads

National consensus recommendations on patient-centered care for ductal carcinoma in situ.

Breast Cancer Res Treat 2019 Jan 9. Epub 2019 Jan 9.

Department of Surgery, University of British Columbia, Vancouver, Canada.

Purpose: The purpose of this research was to generate recommendations on strategies to achieve patient-centered care (PCC) for ductal carcinoma in situ (DCIS).

Methods: Thirty clinicians (surgeons, medical/radiation oncologists, radiologists, nurses, navigators) who manage DCIS and 32 DCIS survivors aged 18 or older were nominated. Forty-six recommendations to support PCC for DCIS were derived from primary research, and rated in a two-round Delphi process from March to June 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05132-zDOI Listing
January 2019
2 Reads

Three-dimensional tumor visualization of invasive breast carcinomas using whole-mount serial section histopathology: implications for tumor size assessment.

Breast Cancer Res Treat 2019 Jan 5. Epub 2019 Jan 5.

Departments of Medical Biophysics and Medical Imaging, Faculty of Medicine, University of Toronto, Toronto, Canada.

Purpose: Linear tumor size (T-size) estimated with conventional histology informs breast cancer management. Previously we demonstrated significant differences in margin and focality estimates using conventional histology versus digital whole-mount serial sections (WMSS). Using WMSS we can measure T-size or volume. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05122-7DOI Listing
January 2019
1 Read

Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.

Breast Cancer Res Treat 2019 Jan 5. Epub 2019 Jan 5.

Women's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada.

Purpose: Women with an inherited germline BRCA1 mutation have a high lifetime risk of developing breast cancer. We have previously shown that, among BRCA mutation carriers, incidence rates of breast cancer vary by country of residence.

Methods: In the current study, we prospectively calculated the cumulative and annual incidence rates of incident breast cancer, contralateral breast cancer and ipsilateral breast cancer recurrence among BRCA1 mutation carriers in Poland. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05076-wDOI Listing
January 2019
2 Reads

Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior.

Breast Cancer Res Treat 2019 Jan 4. Epub 2019 Jan 4.

Department of Pathology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Background: Epithelial-to-mesenchymal transition (EMT) has been implicated as an important step in the development of distant metastases. We therefore wished to study EMT status of primary breast carcinomas from patients who during follow-up developed distant metastases.

Methods: mRNA expression profiles of primary breast carcinoma samples (n = 151) from patients who developed metastatic disease were analyzed and EMT status was designated using a previously described EMT-core signature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05089-5DOI Listing
January 2019
3 Reads

Expression of Lamin A/C in early-stage breast cancer and its prognostic value.

Breast Cancer Res Treat 2019 Jan 4. Epub 2019 Jan 4.

Division of Breast Surgery, The University of Nottingham, Nottingham, UK.

Purpose: Lamins A/C, a major component of the nuclear lamina, play key roles in maintaining nuclear integrity, regulation of gene expression, cell proliferation and apoptosis. Reduced lamin A/C expression in cancer has been reported to be a sign of poor prognosis. However, its clinical significance in breast cancer remains to be defined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05092-wDOI Listing
January 2019
1 Read

Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?

Breast Cancer Res Treat 2019 Jan 4. Epub 2019 Jan 4.

Department of Surgical Oncology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.

Objective: This study aims to evaluate whether extracapsular extension (ECE) in the sentinel lymph node (SLN) is associated with involvement of ≥ 4 lymph node metastases at completion axillary lymph node dissection (ALND) and the effect on 5-year disease-free survival (DFS) and 10-year overall survival (OS). ECE in a SLN is usually a contraindication for omitting completion ALND in cT1-2N0 breast cancer patients treated with breast-conserving therapy and 1-2 positive SLN(s).

Methods: All cT1-2N0 breast cancer patients with 1-3 positive SLN(s) who underwent ALND between 2005 and 2008 were selected from the Netherlands Cancer Registry. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-018-05074-y
Publisher Site
http://dx.doi.org/10.1007/s10549-018-05074-yDOI Listing
January 2019
12 Reads